Stock Watch: When Development Goes Too Far

Beware R&D Organizations With Unfettered Access To Clinical Trial Budgets

01 Oct 2024

• By Andy Smith

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch Image, Andy Smith — ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Two of the most formative experiences I gained working as the commercial person within pharmaceutical development teams involved the inability to predict either the absence of patients or the absence of a viable market for products under development.

As the largest items of biotech and pharma companies’ operational expenditure, clinical trials are subject to rigorous planning and monitoring....